Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
1.030
-0.030 (-2.83%)
At close: Nov 18, 2026, 4:00 PM EST
1.015
-0.015 (-1.48%)
Pre-market: Nov 19, 2026, 4:40 AM EST
Cellectis Employees
As of December 31, 2025, Cellectis had 229 total employees, including 224 full-time and 5 part-time employees. The number of employees increased by 7 or 3.15% compared to the previous year.
Employees
229
Change (1Y)
7
Growth (1Y)
3.15%
Revenue / Employee
$140,166
Profits / Employee
-$556,227
Market Cap
78.84M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 229 | 7 | 3.15% | 224 | 5 |
| Dec 31, 2024 | 222 | 1 | 0.45% | 216 | 6 |
| Dec 31, 2023 | 221 | -16 | -6.75% | 216 | 5 |
| Dec 31, 2022 | 237 | -63 | -21.00% | 231 | 6 |
| Dec 31, 2021 | 300 | 19 | 6.76% | 294 | 6 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Coherus Oncology | 145 |
| Seer, Inc. | 124 |
| Rani Therapeutics Holdings | 71 |
| Tenaya Therapeutics | 70 |
| Anavex Life Sciences | 34 |
| Genelux | 26 |
| TuHURA Biosciences | 22 |
| Tenax Therapeutics | 16 |
CLLS News
- 5 days ago - What Cellectis (CLLS) Said on Its Q3 Earnings Call - MarketBeat
- 6 days ago - Cellectis Earnings Call Transcript: Q3 2026 - Transcripts
- 6 days ago - Cellectis Earnings release: Q3 2026 - Filings
- 6 days ago - Cellectis Earnings release: Q3 2026 - Filings
- 6 days ago - Cellectis Slides: Corporate presentation - Filings
- 6 days ago - Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update - GlobeNewsWire
- 9 days ago - Cellectis to Report Third Quarter Financial Results on November 12, 2026 - GlobeNewsWire
- 22 days ago - Cellectis S.A. Presents Preclinical Data Highlighting Efficient APOC3 Editing and Marked Triglyceride Reduction with .HEAL-101 at ESGCT 2026 - Nasdaq